News & Updates

CameL at 5 years: 1L camrelizumab plus chemo maintains long-term OS benefit
CameL at 5 years: 1L camrelizumab plus chemo maintains long-term OS benefit
19 Dec 2024
Pembrolizumab extends survival in advanced melanoma
Pembrolizumab extends survival in advanced melanoma
18 Dec 2024 byStephen Padilla

Patients with advanced melanoma achieve long-term survival with the use of pembrolizumab, as shown by the results of the 10-year follow-up of the phase III KEYNOTE-006 study.

Pembrolizumab extends survival in advanced melanoma
18 Dec 2024
Salbutamol may lower risk, improve prognosis of prostate cancer
Salbutamol may lower risk, improve prognosis of prostate cancer
14 Dec 2024

The incidence of prostate cancer is reduced among individuals treated with salbutamol, a short-acting beta-2 adrenergic agonist, according to a study.

Salbutamol may lower risk, improve prognosis of prostate cancer
14 Dec 2024